Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMEB8CG)

Drug Name

1G244 Drug Info

Synonyms

1G244; CHEMBL1814633; (2~{S})-2-azanyl-4-[4-[bis(4-fluorophenyl)methyl]piperazin-1-yl]-1-(1,3-dihydroisoindol-2-yl)butane-1,4-dione; GTPL8551; SCHEMBL19350285; C29H30N4O2F2; ZINC14949370; BDBM50350169; AKOS030528223; 847928-32-9; (S)-2-amino-4-(4-(bis(4-fluorophenyl)methyl)piperazin-1-yl)-1-(isoindolin-2-yl)butane-1,4-dione; Y0432

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 56658139
TTD Drug ID: DMEB8CG

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Patented Agent(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Dipeptidyl peptidase 8 (DPP-8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Talabostat	DM1IZ5D	Constitutional neutropenia	4B00.0	Phase 3	[2]
BXCL701	DMBPUIK	Prostate cancer	2C82.0	Phase 1/2	[3]
Thiomorpholine derivative 1	DMZP6KR	N. A.	N. A.	Patented	[4]
Thiomorpholine derivative 2	DMWOK1D	N. A.	N. A.	Patented	[4]
PMID20684603C24dd	DMWZK9U	Discovery agent	N.A.	Investigative	[5]
PMID15664838C18	DM93RKC	Discovery agent	N.A.	Investigative	[6]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Drug(s)

Drug(s) Targeting Dipeptidyl peptidase 9 (DPP-9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Talabostat	DM1IZ5D	Constitutional neutropenia	4B00.0	Phase 3	[2]
BXCL701	DMBPUIK	Prostate cancer	2C82.0	Phase 1/2	[3]
Thiomorpholine derivative 1	DMZP6KR	N. A.	N. A.	Patented	[4]
Thiomorpholine derivative 2	DMWOK1D	N. A.	N. A.	Patented	[4]
PMID20684603C24dd	DMWZK9U	Discovery agent	N.A.	Investigative	[5]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Dipeptidyl peptidase 8 (DPP-8)	TTJGLZF	DPP8_HUMAN	Inhibitor	[1]
Dipeptidyl peptidase 9 (DPP-9)	TTNDUL7	DPP9_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Biochemistry, pharmacokinetics, and toxicology of a potent and selective DPP8/9 inhibitor. Biochem Pharmacol. 2009 Jul 15;78(2):203-10.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma. J Immunother Cancer. 2021 Nov;9(11):e002837.
4	DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36.
5	Discovery of 6-(aminomethyl)-5-(2,4-dichlorophenyl)-7-methylimidazo[1,2-a]pyrimidine-2-carboxamides as potent, selective dipeptidyl peptidase-4 (DPP4) inhibitors. J Med Chem. 2010 Aug 12;53(15):5620-8.
6	Novel isoindoline compounds for potent and selective inhibition of prolyl dipeptidase DPP8. Bioorg Med Chem Lett. 2005 Feb 1;15(3):687-91.